Johnson &a; Johnson Development Corporation
Johnson &a; Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Business Model: B2C B2B
Revenue: $16.3M
Employees: 2-10
Rankings
Detailed Johnson &a; Johnson Development Corporation Information
Geographic Data
Address: 410 George St
City: New Brunswick
State: NJ
Zip: 08901
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Johnson &a; Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson &a; Johnson. JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, JJDC determines the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson &a; Johnson. JJDC plays an integral role in the identification of new business opportunities outside of Johnson &a; Johnson’s traditional portfolio and market presence. JJDC identifies new market opportunities and develops new businesses in emergent health care sectors while also creating support venture investments in alignment with the strategic objectives of Johnson &a; Johnson operating companies.
Contact Phone:
+17325243214
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 2/2009 | ImaCor | Series A | 0 |
| 9/2012 | Catalyst Biosciences | Post-IPO Equity | 13.4M |
| 2/2016 | Cala Health | Series B | 0 |
| 6/2010 | Aquinox Pharmaceuticals | Series B | 0 |
| 4/2002 | Replidyne | Series A | 13M |
| 12/2014 | Padlock Therapeutics | Series A | 23M |
| 4/2010 | Biocartis | Series B | 40M |
| 9/2014 | Biocartis | Series F | 0 |
| 1/2011 | 23andMe | Series C | 9M |
| 10/2008 | Biolex Therapeutics | Series D | 0 |
| 9/2002 | KuDOS Pharmaceuticals Ltd | Series C | 45.2M |
| 1/2012 | PowerVision | Series C | 12.5M |
| 6/2001 | NitroMed | Series E | 0 |
| 1/2005 | Biolex Therapeutics | Venture Round | 8M |
| 8/2005 | 7TM Pharma | Venture Round | - |
| 5/2002 | eNeura Therapeutics | Series A | 1M |
| 9/2004 | Vascular Architects | Series E | 0 |
| 6/2012 | PhaseBio Pharmaceuticals | Series B | 23M |
| 7/2013 | CVRx | Series F | 0 |
| 1/2009 | 7TM Pharma | Venture Round | 0 |
| 6/2007 | Aquinox Pharmaceuticals | Series A | 14.5M |
| 2/2012 | Celladon | Venture Round | 43M |
| 5/2007 | CVRx | Series D | 65M |
| 11/2009 | Celladon | Series C | 21.8M |
| 3/2005 | TorreyPines Therapeutics | Series C | 0 |
| 12/2012 | Biocartis | Series D | 0 |
| 6/2009 | Pronota | Series B | 7.4M |
| 8/2003 | Biolex Therapeutics | Venture Round | 0 |
| 1/2006 | Archus Orthopedics | Series C | 35M |
| 6/2013 | Protagonist Therapeutics | Series B | 0 |
| 6/2013 | Vedanta Biosciences | Venture Round | - |
| 3/2004 | InSound Medical | Series D | 17.2M |
| 11/2001 | Locus Pharmaceuticals | Series C | 0 |
| 11/2000 | Locus Pharmaceuticals | Series B | 0 |
| 3/2011 | Astute Medical | Series B | 13M |
| 5/2010 | Breathe Technologies | Series C | 23M |
| 11/2010 | 23andMe | Series C | 22.2M |
| 8/2008 | Neuron Systems | Series A | 9M |
| 5/2010 | Astute Medical | Series B | 26.5M |
| 5/2000 | Global Telemedix | Series B | 0 |
| 9/2009 | Neotract | Series B | 28.1M |
| 3/2006 | 7TM Pharma | Series C | 0 |
| 9/2009 | NovoCure | Venture Round | - |
| 8/2004 | Othera Pharmaceuticals | Series B | 0 |
| 6/2007 | 7TM Pharma | Series D | 22M |
| 10/2010 | Intio | Series B | 8.1M |
| 4/2006 | Pronota | Series A | 7.8M |
| 5/2012 | Mitralign | Series D | 0 |
| 1/2012 | Pronota | Series C | 4.8M |
| 3/2017 | Grail | Series B | 0 |
| 6/2011 | Spinal Modulation | Series D | 0 |
| 10/2003 | OmniSonics Medical Technologies | Series C | 43M |
| 1/2003 | Vascular Architects | Series D | 0 |
| 11/2003 | CardioMEMS | Series B | 0 |
| 7/2013 | ViaCyte | Series C | 10.6M |
| 5/2006 | ViaCyte | Venture Round | 0 |
| 7/2004 | Intrapace | Series C | 0 |
| 1/2004 | Animas Corporation | Venture Round | 16.9M |
| 3/2003 | Sopherion Therapeutics | Series A | 0 |
| 1/2010 | PhaseBio Pharmaceuticals | Series B | 25M |
| 7/2005 | Ilypsa | Series B | 36M |
| 7/2000 | Lumenos | Series B | 34M |
| 5/2021 | Binx Health | Series E | 0 |
| 12/2000 | InfoMedics | Venture Round | 10M |
| 5/2009 | iScience Interventional | Series F | 20.5M |
| 11/2010 | Syntaxin | Series C | 29M |
| 1/2008 | Arbor Surgical Technologies | Series C | 0 |
| 12/2007 | Mitralign | Series C | 0 |
| 10/2004 | Acuity Pharmaceuticals | Series B | 0 |
| 2/2014 | Thesan Pharmaceuticals | Series B | 49M |
| 4/2013 | Aquinox Pharmaceuticals | Series C | 0 |
| 6/2014 | Aduro BioTech | Series C | 55.7M |
| 7/2008 | CVRx | Series E | 0 |
| 6/2003 | Orqis Medical | Series C | 25M |
| 10/2007 | Direct Flow Medical | Series B | 27M |
| 9/2002 | CellGate | Series D | 10M |
| 7/2007 | ViaCyte | Series C | 0 |
| 3/2004 | BioRexis | Series B | 30M |
| 7/2002 | Transvascular | Series D | 10.8M |
| 3/2015 | PhaseBio Pharmaceuticals | Series C | 0 |
| 6/2014 | Navitor Pharmaceuticals | Series A | 23.5M |
| 11/2013 | Biocartis | Series E | 0 |
| 5/2005 | Mazor Robotics | Series B | 10M |
| 2/2017 | Fusion Pharmaceuticals | Series A | 0 |
| 1/2011 | Zeo | Series C | 0 |
| 7/2013 | ReVision Optics | Series E | 55M |
| 12/2000 | Sleep Solutions | Series D | 8M |
| 6/2013 | Rodin Therapeutics | Seed Round | - |
| 5/2014 | Rodin Therapeutics | Series A | 12.9M |
| 10/2007 | Syntaxin | Series B | 32M |
| 8/2011 | NeuroPace | Venture Round | 0 |
| 10/2007 | Tengion | Series C | 33M |
| 6/2006 | Tengion | Series B | 50M |
| 6/2009 | CoAxia | Series D | 21.5M |
| 7/2013 | NeuroPace | Venture Round | 18M |
| 1/2015 | Willow | Series A | 15M |
| 1/2012 | iScience Interventional | Venture Round | 2.8M |
| 10/2003 | Critical Therapeutics,Inc. | Series B | 56M |
| 6/2000 | iKnowMed | Series C | 30.7M |
| 12/2009 | Genocea Biosciences | Series B | 25.7M |
| 7/2003 | InSound Medical | Series D | 6.5M |
| 10/2007 | PhaseBio Pharmaceuticals | Venture Round | 6.6M |
| 10/2005 | Light Sciences Oncology | Series A | 35M |
| 4/2013 | Catalyst Biosciences | Post-IPO Equity | 5.1M |
| 11/2016 | ReVision Optics | Venture Round | 32M |
| 10/2012 | Genocea Biosciences | Series C | 30M |
| 8/2005 | Tengion | Series A | 39M |
| 7/2011 | Binx Health | Series B | 27.1M |
| 10/2013 | Merus | Series B | 42.2M |
| 12/2008 | Catalyst Biosciences | Post-IPO Equity | 40M |
| 4/2007 | CymaBay Therapeutics | Series D | 32M |
| 3/2013 | CoStim Pharmaceuticals | Series A | 22M |
| 7/2011 | Nevro | Series B | 58M |
| 6/2012 | Astute Medical | Series C | 40.4M |
| 1/2011 | Genocea Biosciences | Series B | 35M |
| 3/2009 | GI Dynamics | Series C | 0 |
| 9/2005 | Biolex Therapeutics | Series B | 36M |
| 5/2007 | Biolex Therapeutics | Series C | 30M |
| 8/2008 | Brainsgate | Series C | 27.5M |
| 3/2013 | Nevro | Series C | 0 |
| 8/2007 | Molecular Partners | Series A | 15.6M |
| 4/2012 | Direct Flow Medical | Venture Round | 0 |
| 3/2000 | MEDCHANNEL | Series B | 42M |
| 12/2009 | Molecular Partners | Series B | 44.2M |
| 11/2004 | Corthera | Series B | 15M |
| 5/2014 | Inspire Medical Systems | Series E | 0 |
| 7/2020 | CVRx | Private Equity Round | 0 |
| 8/2019 | CVRx | Series G | 93M |
| 4/2014 | Binx Health | Series B | 0 |
| 7/2004 | Accumetrics | Series B | 0 |
| 7/2003 | Immunicon | Series F | 24.8M |
| 3/2007 | Axial Biotech | Series B | 15.3M |
| 1/2014 | TopiVert | Venture Round | 7.4M |
| 11/2014 | La Lumiere | Series B | 20M |
| 3/2007 | Orqis Medical | Series D | 12M |
| 1/2014 | PowerVision | Series D | 0 |
| 4/2013 | ReVision Optics | Equity | 15M |
| 3/2000 | Cyrano Sciences | Venture Round | 23M |
| 12/2005 | Light Sciences Oncology | Series A | 32M |
| 3/2009 | GetWellNetwork | Series C | 10M |
| 11/2009 | Spinal Modulation | Series C | 27.4M |
| 3/2000 | InfoMedics | Venture Round | 6M |
| 11/2011 | Biocartis | Series C | 95.8M |
| 7/2006 | InSound Medical | Series E | 18.9M |
| 9/2014 | Inivata | Venture Round | 6.6M |
| 2/2008 | InSound Medical | Series E | 11M |
| 10/2009 | Direct Flow Medical | Series C | 40M |
| 11/2013 | Pulmocide | Series A | 27.6M |
| 4/2001 | Vascular Architects | Series C | 20M |
| 3/2022 | Osteal Therapeutics | Series B | 0 |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 10/2007 | Optherion | Series A | 37M |
| 1/2009 | Acclarent | Venture Round | 26M |
| 2/2013 | OptiScan Biomedical | Private Equity Round | 30.7M |
| 1/2002 | Sleep Solutions | Series E | 7M |
| 10/2009 | Sleep Solutions | Series F | 20M |
| 10/2003 | Sleep Solutions | Venture Round | 6.1M |
| 5/2000 | Sleep Solutions | Series C | 3M |
| 8/2009 | Neurosearch | Venture Round | 14.3M |
| 3/2022 | Osteal Therapeutics | Series B | 0 |
| 5/2021 | Binx Health | Series E | 0 |
| 7/2020 | CVRx | Private Equity Round | 0 |
| 8/2019 | CVRx | Series G | 0 |
| 3/2017 | Grail | Series B | 0 |
| 2/2017 | Fusion Pharmaceuticals | Series A | 0 |
| 11/2016 | ReVision Optics | Venture Round | 0 |
| 2/2016 | Cala Health | Series B | 0 |
| 3/2015 | PhaseBio Pharmaceuticals | Series C | 0 |
| 1/2015 | Willow | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
